AstraZeneca’s nasal COVID-19 vaccine fails clinical trial

By MSN

AstraZeneca and Oxford University scientists on Tuesday said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection.

In a statement issued on Tuesday, the University of Oxford said that an antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing.

According to a report by the news agency Reuters, the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination.

Currently, scientists across the world have high hopes for the impact of nasal vaccines against COVID-19. The researchers believe that nasal vaccines have the potential of treating the virus and they can reportedly prompt an